Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Joyce

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Cancer|November 6, 2009
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter StudyBrad S Kahl, Nancy L Bartlett, John P Leonard, et al.
Haematologica|November 13, 2012
Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphomaJeffrey A Barnes, Eric Jacobsen, Yang Feng, et al.
British Journal of Haematology|April 7, 2009
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomasJennifer R Brown, Jonathan W Friedberg, Yang Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaThomas E Witzig, Leo I Gordon, Fernando Cabanillas, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2010
Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28Jacalyn Rosenblatt, Zekui Wu, Baldev Vasir, et al.
British Journal of Haematology|January 6, 2016
A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphomaPhilippe Armand, Robert Redd, Jad Bsat, et al.
Blood|June 7, 2015
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphomaSalvia Jain, Dina Stroopinsky, Li Yin, et al.
Blood|October 30, 2010
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myelomaJacalyn Rosenblatt, Baldev Vasir, Lynne Uhl, et al.
JID Innovations : Skin Science From Molecules to Population Health|March 24, 2023
Development and Narrow Validation of Computer Vision Approach to Facilitate Assessment of Change in Pigmented Cutaneous LesionsWilliam F Maguire, Paul H Haley, Catherine M Dietz, et al.
Blood|May 23, 2013
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphomaMatthew J Matasar, Myron S Czuczman, Maria Alma Rodriguez, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Cancer|November 6, 2009
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter StudyBrad S Kahl, Nancy L Bartlett, John P Leonard, et al.
Haematologica|November 13, 2012
Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphomaJeffrey A Barnes, Eric Jacobsen, Yang Feng, et al.
British Journal of Haematology|April 7, 2009
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomasJennifer R Brown, Jonathan W Friedberg, Yang Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaThomas E Witzig, Leo I Gordon, Fernando Cabanillas, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2010
Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28Jacalyn Rosenblatt, Zekui Wu, Baldev Vasir, et al.
British Journal of Haematology|January 6, 2016
A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphomaPhilippe Armand, Robert Redd, Jad Bsat, et al.
Blood|June 7, 2015
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphomaSalvia Jain, Dina Stroopinsky, Li Yin, et al.
Blood|October 30, 2010
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myelomaJacalyn Rosenblatt, Baldev Vasir, Lynne Uhl, et al.
JID Innovations : Skin Science From Molecules to Population Health|March 24, 2023
Development and Narrow Validation of Computer Vision Approach to Facilitate Assessment of Change in Pigmented Cutaneous LesionsWilliam F Maguire, Paul H Haley, Catherine M Dietz, et al.
Blood|May 23, 2013
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphomaMatthew J Matasar, Myron S Czuczman, Maria Alma Rodriguez, et al.
Pageof 4